Calidi Biotherapeutics, Inc. (CLDI) Dividend History

Calidi Biotherapeutics, Inc. (CLDI) is a biotechnology company focused on developing advanced cell-based immunotherapies for cancer and infectious diseases. The company leverages proprietary platform technologies, including its tumor-targeting and immune-activating cell systems, to create innovative treatments aimed at improving patient outcomes.

Dividend History

Calidi Biotherapeutics, Inc. currently does not pay dividends

Company News

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

Benzinga

Featured Companies: CRSP CTMX IBRX VRTX
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics, a clinical-stage biotechnology company, announced the closing of a $4.25 million public offering of 5,000,000 shares of common stock at $0.85 per share. The company is developing targeted antitumor virotherapies.

GlobeNewswire Inc.
Calidi Biotherapeutics announces 1-for-10 reverse stock split - Investing.com

Calidi Biotherapeutics, a biotechnology company, announced a 1-for-10 reverse stock split to enhance shareholder value. The move aims to increase the per-share trading price and potentially satisfy listing requirements.

Investing.com

Page data last updated 07/23/2025 08:27:07 UTC